SCHEMBL1606356

SCHEMBL1606356

NC(=S)N[C@H]1C[C@H]2CC[C@H]1C2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.56
MAPT P10636 3/20 0.56
GRIN2D O15399 2/20 0.56
GRIN3B O60391 2/20 0.56
GRIN1 Q05586 2/20 0.56
GRIN2A Q12879 2/20 0.56
GRIN2B Q13224 2/20 0.56
GRIN2C Q14957 2/20 0.56
GRIN3A Q8TCU5 2/20 0.56
EPHX2 P34913 3/20 0.49
ALDH1A1 P00352 6/20 0.47
GAA P10253 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
EPHX1 P07099 1/20 0.47
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14531196 1.00 SIGMAR1 (0.56) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL2218573 1.00 SIGMAR1 (0.56) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL1604532 1.00 SIGMAR1 (0.56) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL1606353 1.00 SIGMAR1 (0.56) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3067249 0.86 MAPT (0.60) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3064313 0.86 SIGMAR1 (0.54) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3082238 0.83 MAPT (0.70) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3071087 0.83 MAPT (0.59) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3058571 0.82 MAPT (0.51) SIGMAR1MAPTGRIN2DGRIN3BGRIN1
SCHEMBL3065619 0.81 SIGMAR1 (0.50) SIGMAR1MAPTGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB 2012-01-12 US disclosed
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. 2011-04-07 US disclosed
US-7807700-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN INC. (US) 2010-10-05 US disclosed
EP-1753736-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC (US) 2008-12-17 EP disclosed
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2008-02-21 US disclosed
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 AMGEN INC. 2007-12-06 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 US disclosed
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 SIGMAR1 1132/4885MAPT 3588/4885GRIN2D 1509/4885
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 SIGMAR1 1132/4885MAPT 3588/4885GRIN2D 1509/4885
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 SIGMAR1 2137/4885MAPT 2825/4885GRIN2D 1802/4885
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 SIGMAR1 1132/4885MAPT 3588/4885GRIN2D 1509/4885
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 SIGMAR1 1132/4885MAPT 3588/4885GRIN2D 1509/4885
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 HSD11B1, HSD3B1, HSD17B1 SIGMAR1 1309/4885MAPT 3804/4885GRIN2D 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.